PDS Biotech’s PDS01ADC Delivers Impressive 78% Response Rate in Advanced Colorectal Cancer Trial
PDS Biotech drug PDS01ADC improved tumor shrinkage and survival in colorectal cancer trials, showing strong early results.
/ 2 items
PDS Biotech drug PDS01ADC improved tumor shrinkage and survival in colorectal cancer trials, showing strong early results.
PDS Biotechnology updates Phase 3 trial protocol with FDA to potentially speed up approval of PDS0101 for HPV-related head and neck cancer treatment.